Clinical trial
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder
NCT07276997 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 18, 2025
- Completion date
- September 30, 2027
- Enrollment
- 195 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.